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Abstract
Clinical and serological profiles of idiopathic and drug-induced
autoimmune diseases can be very similar. We compared data
from idiopathic and antithyroid drug (ATD)-induced
antineutrophil cytoplasmic antibody (ANCA)-positive patients.
From 1993 to 2003, 2474 patients were tested for ANCA in the
Laboratory for Allergy and Clinical Immunology in Belgrade. Out
of 2474 patients, 72 (2.9%) were anti-proteinase 3 (PR3)- or
anti-myeloperoxidase (MPO)-positive and their clinical and
serological data were analyzed. The first group consisted of
ANCA-associated idiopathic systemic vasculitis (ISV)
diagnosed in 56/72 patients: 29 Wegener's granulomatosis
(WG), 23 microscopic polyangiitis (MPA) and four Churg-
Strauss syndrome. The second group consisted of 16/72
patients who became ANCA-positive during ATD therapy (12
receiving propylthiouracil and four receiving methimazole). We
determined ANCA and antinuclear (ANA) antibodies by indirect
immunofluorescence; PR3-ANCA, MPO-ANCA, anticardiolipin
(aCL) and antihistone antibodies (AHA) by ELISA; and
cryoglobulins by precipitation. Complement components C3
and C4, alpha-1 antitrypsin (α 1 AT) and C reactive protein (CR-
P) were measured by nephelometry. Renal lesions were present
in 3/16 (18.8%) ATD-treated patients and in 42/56 (75%) ISV
patients (p <0.001). Skin lesions occurred in 10/16 (62.5%)
ATD-treated patients and 14/56 (25%) ISV patients (p <0.01).
ATD-treated patients more frequently had MPO-ANCA, ANA,
AHA, aCL, cryoglobulins and low C4 (p <0.01). ISV patients
more frequently had low α 1 AT (p = 0.059) and high CR-P (p
<0.001). Of 16 ATD-treated patients, four had drug-induced
ANCA vasculitis (three MPA and one WG), while 12 had lupus-
like disease (LLD). Of 56 ISV patients, 13 died and eight
developed terminal renal failure (TRF). There was no lethality in
the ATD-treated group, but 1/16 with methimazole-induced
MPA developed pulmonary-renal syndrome with progression to
TRF. ANCA-positive ISV had a more severe course in
comparison with ATD-induced ANCA-positive diseases.
Clinically and serologically ANCA-positive ATD-treated patients
can be divided into two groups: the first consisting of patients
with drug-induced WG or MPA which resemble ISV and the
second consisting of patients with LLD. Different serological
profiles could help in the differential diagnosis and adequate
therapeutic approach to ANCA-positive ATD-treated patients
with symptoms of systemic disease.
Introduction
Antineutrophil cytoplasmic antibodies (ANCA) specific for
proteinase 3 (PR3) and myeloperoxidase (MPO) are associ-
ated with necrotizing vasculitides, especially Wegener's
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drug; BVAS = Birmingham Vasculitis Activity Score; CR-P = C reactive protein; DID = drug-induced diseases; DIV = drug-induced vasculitis; ELISA 
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granulomatosis (WG), microscopic polyangiitis (MPA) and idi-
opathic crescentic glomerulonephritis [1]. Pathogenesis of
ANCA-associated idiopathic systemic vasculitides (ISV) is not
well understood, but it has been shown that ANCA-activated
neutrophils contribute to oxidative and proteolytic damage of
blood vessels [2]. Cytoplasmic PR3-ANCA has high specifi-
city (99%) for the newly diagnosed WG [3]. Perinuclear MPO-
ANCA is a good serological marker for MPA, but it can also be
found in patients with systemic lupus erythematosus (SLE),
rheumatoid arthritis, drug-induced vasculitides (DIV), etc [4].
ANCA-associated ISV are rare and their annual incidence is
approximately 9.5 per million (in Germany) [3]. Although WG
and MPA belong to the ISV group, they can be triggered by
some chemicals, viral and bacterial infections and certain
drugs, among which antithyroid drugs (ATDs) are very com-
mon [5]. Propylthiouracil (PTU) and methimazole (MM) may
induce ANCA-positive vasculitides [6].
The clinical and serological profiles of idiopathic and drug-
induced autoimmune diseases (DIDs) can be very similar.
Contrary to idiopathic vasculitides, DIDs have a milder course
and often do not necessitate cytotoxic drug therapy [5]. Patho-
genesis and clinical/serological characteristics of ANCA-
associated diseases triggered by ATD have not been suffi-
ciently investigated. In a retrospective study, we compared




From 1993 to 2003, 2474 patients were tested for ANCA in
the Laboratory for Allergy and Clinical Immunology in Bel-
grade, and 72/2474 (2.9%) were PR3-ANCA or MPO-ANCA
positive. The maximal follow-up period was 11 years and the
minimal was 6 months, while the median follow-up time was
4.5 years.
PR3-ANCA- and MPO-ANCA-positive patients were divided
into two groups. The first group consisted of ANCA-associ-
ated ISV that was diagnosed in 56/72 (77.7%) patients (29
WG, 23 MPA and four Churg-Strauss syndrome) according to
Chapel Hill Consensus Conference [7]. Disease activity was
assessed according to the Birmingham Vasculitis Activity
Score (BVAS) [8]. A biopsy was taken from 47/56 patients
(biopsies were not performed in the other nine patients due to
poor/critical general condition). Kidney biopsy was performed
in 38 patients (25 segmental necrotizing glomerulonephritis
(SNGN) with cellular and fibrous crescents, four SNGN with-
out crescents, six SNGN with arteritis and three mesangial
proliferation). Lung biopsy was performed in 10 patients (four
granulomatous inflammation with multinucleated giant cells
with foci of neutrophils, leucocytoclasia and necrosis; two
hemorrhagic alveolar capillaritis with septal infiltration of neu-
trophils and necrosis; and four perivascular hemorrhage with
mixed infiltrate composed of neutrophils and mononuclear
cells). Skin biopsy was performed in six patients (four leuco-
cytoclastic vasculitis and two swollen endothelial cells, neu-
trophil infiltration without frank fibrinoid necrosis); nasal
lesions in four (one giant cell granuloma and three mucosal
neutrophil infiltration); and lymph nodes in one patient
(perivascular infiltration of neutrophils and lympho/mono-
cytes). Complete blood count, renal function tests, proteinuria
and urine examination were done at the time of diagnosis and
then serially during the follow-up period. Initially all patients
were treated with cyclophosphamide (six intravenous (iv)
pulses at 700 mg/m2 or 2 mg/kg/day orally) in combination
with prednisone at 1 mg/kg/day in most patients. A few
patients with milder disease received cyclophosphamide with
prednisone at 0.5 mg/kg/day.
The second group, 16/72 (22.3%), consisted of ANCA-posi-
tive patients who developed symptoms of systemic disease
during ATD therapy. The diagnosis of Graves' disease (GD)
and Hashimoto thyroiditis (HT) was made according to estab-
lished criteria [9]. One patient with GD was in the fifth month
of pregnancy, one had Pluriglandular Autoimmune Syndrome
type II and the only male person with GD was in remission from
IgA nephropathy. Of the 16 patients, six were taking PTU for a
relapse of hyperthyroidism. The majority of patients (9/16) had
a maintenance therapy with PTU at 50–150 mg/day or with
MM at 5–15 mg/day. Florid hyperthyroidism was present in 7/
16 individuals, and these patients were treated with 200–400
mg/day of PTU or with 15–40 mg/day of MM. Biopsy was
taken from 14/16 ATD-treated ANCA-positive patients. Skin
biopsy was performed in 10 patients (eight leucocytoclastic
vasculitis with fibrinoid necrosis and two swollen endothelial
cells with edema), kidney biopsy in two (two SNGN with
fibrous crescents and one SNGN without crescents) and lung
biopsy in two (one granulomatous inflammation with focus of
neutrophils, leucocytoclasia and necrosis and one perivascu-
lar mixed infiltrate composed of neutrophils and mononuclear
cells). Immunosuppressive therapy was given to 6/16 ATD-
treated patients (corticosteroids in three and cyclophospha-
mide iv pulses or orally in three). A pregnant patient with exten-
sive cutaneous necroses was treated with intravenous
methylprednisolone pulses (three pulses of 500 mg) followed
by oral prednisone at 0.5 mg/kg with gradual dose tapering.
Methods
All samples were obtained at the time of diagnosis and none
of the patients had previously received immunosuppressive
treatment. IgG ANCA titers were determined at the initial visit
and at least 6 months thereafter using an indirect immunofluo-
rescence (IIF) assay with 'in-house' ethanol-fixed neutrophil
preparation as previously described, starting with a titer of
1:16 [10]. PR3-ANCA and MPO-ANCA specificity (cut-off 15
U/ml) was confirmed by direct ELISA (Varelisa; Pharmacia
Upjohn Diagnostics, Freiburg, Germany).Available online http://arthritis-research.com/content/7/5/R1072
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Antinuclear (ANA) IgG antibodies were detected by IIF using
HEp 2 cells (Mast Diagnostica, Reinfeld, Germany). Anti-
dsDNA IgG antibodies were detected by IIF on Crithidia luci-
lliae (Mast Diagnostica). The concentration of specific anti-
bodies (RNP, Sm, SS-A, SS-B, Scl 70, CENP and Jo) in ANA-
positive sera were measured (cut-off 8 U/ml) by commercial
direct ELISA (Varelisa).
Concentrations of anticardiolipin antibodies (aCL) IgG and
IgM, anti-beta (β )-2 glycoprotein (GP) I, IgG and IgM and anti-
histone antibodies (AHA) were measured by commercial
direct ELISA (Varelisa). Antimicrosomal and antithyreoglobulin
IgG antibodies were detected by IIF using primate thyroid
gland as substrate, starting with a titer of 1:20. Concentrations
of C3, C4 component complement, C reactive protein (CR-P)
and alpha-1 antitrypsin (α 1 AT) were measured by nephelom-
etry (Orion Diagnostica, Espoo, Finland). Cryoglobulins were
investigated by the standard procedure [11]. Cryoprecipitate
was analyzed for detection of ANCA by IIF, rheumatoid factor
by nephelometry (Orion Diagnostica) and the presence of par-
aprotein by immunofixation (Binding Site, Birmingham, UK).
Positive sera were analyzed for the presence of hepatitis C
virus by ELISA test (Biokit, Barcelona, Spain).
Statistical analysis
Frequencies of non-parametric characteristics in ISV and DID
groups were compared using the χ 2 test or Fisher's exact test.
Student's t-test was applied in comparisons of continuous var-
iables. Correlations were expressed using Spearman's rank
correlation coefficient. Probability (p) values less than 0.05
were considered statistically significant. Data were analyzed
with SPSS statistical software v10.00 for Windows (SPSS,
Inc, Chicago, IL, USA).
Ethics
Informed consent was obtained from each patient and the Eth-
ics Committee of the Clinical Center of Serbia approved the
study protocol.
Results
In the ATD-associated MPO- or PR3-ANCA-positive group,
there were statistically more women than men (p <0.01) and
patients were significantly younger (p <0.001) in comparison
with patients with ISV (Table 1). The average symptom dura-
tion before diagnosis was significantly shorter in ATD-treated
patients (p <0.001). Mean treatment duration with ATD was
20 ± 6 months (range 6–36 months): PTU was given 25 ± 7
and MM 11 ± 4 months before symptoms occurred. ATDs
were given for longer than the usual 18 months in 12/16
patients. Most of patients in the DID group had GD (81%) and
were treated with PTU (75%).
Idiopathic and ATD-induced ANCA-positive patients were
characterized by a high frequency of arthralgia and myalgia.
On the other hand, ISV patients more frequently had fever,
weight loss, renal manifestations, acute renal failure (ARF),
pulmonal manifestations, pulmonary-renal syndrome, ear/nose
and nervous system manifestations (Table 2).
In the ATD-treated group, only 1/16 patients developed ARF
(SNGN with crescents) with severe pulmonary-renal syn-
drome; 2/16 patients developed hematuria and non-nephrotic
range proteinuria. Only one female patient treated with MM
had nodular lung infiltration pathohistologically verified as
granulomatous vasculitis.
In contrast to patients with ISV, ATD-associated ANCA-posi-
tive patients had skin manifestations more frequently, espe-
cially urticaria-like vasculitis and urticaria (Table 2). Patients
with urticaria-like vasculitis and purpura histologically had leu-
cocytoclastic vasculitis. A pregnant patient with poorly con-
trolled GD had extensive cutaneous necroses and
hemorrhagic bullae, while a patient with pluriglandular
autoimmune syndrome had lower leg ulcerations. Digital
gangrenes and mouth ulcerations were noted only in PR3-
ANCA-positive ISV patients.
Table 1
Characteristics of the PR3/MPO-ANCA-positive patients with idiopathic and antithyroid DIDs
Patients with idiopathic vasculitides 
(n = 56)
Patients with antithyroid DIDs 
(n = 16)
Female sex, n (%) 29 (52) 15 (94)*
Age, years 52.8 ± 10.9 31 ± 9.8**
Range 18–72 20–52
Months between first complaints and ANCA detection 3.8 ± 1.2 2.3 ± 1.1**
Graves' disease/Hashimoto thyroiditis, n 01 3 / 3
Propylthiouracil/methimazole, n 01 2 / 4
Values represent either numbers of patients (%) or mean ± standard deviation. *p < 0.01, **p < 0.001. ANCA, antineutrophil cytoplasmic 
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None of the ATD-treated patients manifested central nervous
system effects, while 1/16 patients had predominantly periph-
eral sensory polyneuropathy that regressed upon drug
withdrawal.
ATD-induced ANCA-positive patients more frequently had
MPO-ANCA, ANA, AHA, IgM aCL, concomitant presence of
both IgM and IgG aCL, IgM anti-β 2 GP I, cryoglobulinemia and
decreased C4 (Table 3). Demonstration of pANCA and
cANCA by IIF correlated with MPO-ANCA and PR3-ANCA
positivity in ELISA, in all except one patient with WG, in whom
cANCA had MPO specificity. In all ANA-positive patients,
ANCA/ANA titer proportion was >2. In the group of ATD-asso-
ciated ANCA-positive patients, 1/16 had anti-DNA antibodies
(titer 1:80), while 1/16 had anti-SSA (an antibody associated
with Sjogren's Syndrome) in a concentration of 30.5 U/ml.
Decreased C4 was found in three individuals with cryoglob-
ulinemia, two of whom had ANA and leucopenia. None of the
three ATD-treated patients with cryoglobilinemia had hepatitis
C virus infection and no rheumatoid factor or paraproteins
were detected in cryoprecipitate. Perinuclear ANCA was
present in cryoprecipitate of one patient. Both patients with
extensive cutaneous necroses had high MPO-ANCA concen-
trations, type III cryoglobilinemia, IgM aCL and slightly
decreased C4.
Analysis of clinical and serological parameters revealed that
the ATD-associated ANCA-positive patients can be divided
into two groups (Table 4). The first group (4/16 patients) had
clinical and serologic parameters similar to patients with ISV.
Among these patients, one had WG and three had MPA
(Table 5). The second group (12/16 patients) had clinical and
Table 2
Initial clinical manifestations in PR3/MPO-ANCA-positive patients with idiopathic vasculitides and antithyroid DIDs
Patients with idiopathic vasculitides (n = 56) Patients with antithyroid DIDs (n = 16)
Systemic 56 (100) 16 (100)
Arthralgia/myalgia 56(100) 16 (100)
Fever >38.5°C 48 (86) 4 (25)***
Weight loss >2 kg a month 47 (84) 5 (31)***
Renal 42 (75) 3 (19)***
Acute renal failure 25 (45) 1(6)**
Proteinuria, hematuria 17 (30) 2 (12)
Lung 28 (50) 3 (19)*
Infiltrate 15 (27) 2 (12)
Nodules 10 (18) 1 (6)
hemoptysis 14 (25) 1 (6)
Pulmonary-renal syndrome 22 (39) 1 (6)*
Skin 14 (25) 10 (62.5)**
Necrosis 11(20) 2 (12)
Gangrene 3 (5) 0
Purpura 5 (9) 1 (6)
Urticaria-like vasculitis 0 5 (31) ***
Urticaria 0 2 (12.5)*
Gastrointestinal tract 7 (12) 0
Ear, nose 15 (27) 0*
Eyes 7 (12) 0
Nervous system 26 (46) 1 (6)**
Central 13 (20) 0
Peripheral 15 (27) 1 (6)
All values represent numbers of patients (%). *p < 0.05 **p < 0.01 ***p < 0.001. ANCA, antineutrophil cytoplasmic antibodies; DID, drug-induced 
autoimmune disease; MPO, myeloperoxidase; PR3, proteinase 3.Available online http://arthritis-research.com/content/7/5/R1072
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serologic parameters typical for MPO-ANCA-associated
lupus-like disease (LLD) [9]. No patient fulfilled criteria for SLE
[12] and primary antiphospholipid syndrome - APS [13].
In the ISV group, at the beginning of the disease, there was no
correlation between cANCA or pANCA titers and BVAS (p >
0.05). Also, in drug-induced MPA patients (Table 5), there was
no correlation between pANCA titers and BVAS (p > 0.05).
All patients with ISV were treated with immunosuppressive
therapy. In ATD-treated patients, only 6/16 patients were
treated with immunosuppressive therapy (Table 5). Although
clinical remission was achieved in all 16 ATD-treated patients
Table 3
Serological parameters in PR3/MPO-ANCA-positive idiopathic vasculitides and antithyroid DIDs
Patients with idiopathic vasculitides (n = 56) Patients with antithyroid DIDs (n = 16)
pANCA 28 (50) 15 (94)**
Median (1/titer) 64 256*
Range (1/titer) 32–256 64–512
MPO-ANCA 29 (52) 15 (94)**
MPO-ANCA (U/ml) 64.3 ± 22 55 ± 19
CANCA 28 (50) 1(6)**
Median (1/titer) 64 64
Range (titer) 1:32–1:256 -
PR3-ANCA 27 (48) 1 (6)**
PR3-ANCA (U/ml) 58.8 ± 17 44
ANA 3 (5) 8 (50)***
Median (1/titer) 40 80
Anti-DNA 0 1 (6)
Anti-histone 0 3(19)**
Anti-SSA 0 1(6)
aCL 6 (11) 9 (56)***
IgG 5 (9) 1 (6)
IgM 0 2 (12.5)*
IgG/IgM 1 (2) 6 (37.5)***
Anti-β 2 GP I 2 (3.5) 4 (25)*
IgG 1 (2) 1 (6)
IgM 1 (2) 3 (19)*
Cryoglobulinemia 0 3 (19)**
Antimicrosomal Ab 1 (2) 13 (81)***
Antithyroglobulin Ab 1 (2) 3 (19)*
Low C4 (<0.1 g/l) 0 3 (19)**
Low α 1 AT (<1.1 g/l) 13 (23) 0
High CR-P (>10 mg/l) 56 (100) 8 (50)***
CR-P mg/l 90 ± 35 46 ± 15**
Leucopenia (<3 × 109/l) 1 (2) 2 (12.5)
All values represent either numbers of patients (%), or mean ± standard deviation, except median and range for p and cANCA titer. *p <0.05, **p 
< 0.01, ***p < 0.001. α 1 AT, alpha-1 antitrypsin; Ab, antibodies; aCL, anticardiolipin antibodies; ANA, antinuclear antibodies; anti-β 2 GP I, anti-
beta 2 glycoprotein I; cANCA, cytoplasmic antineutrophil cytoplasmic antibodies; CR-P, C reactive protein; DID, drug-induced autoimmune 
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after 6 months, ANCA titers slowly declined and only finally
disappeared after 2 years. Also, clinical remission preceded
the disappearance of organ-nonspecific antibodies. Anti-DNA,
AHA and cryoglobulins disappeared in 6 months, while aCL
and anti-β 2 GP I concentrations declined, but persisted for up
to 1.5 years. Clinical remission preceded the disappearance of
ANCA in 6/16 patients who were treated with immunosup-
pressive drugs.
In patients with ISV, induction of clinical remission correlates
with significant ANCA titers reduction (Table 5), and this was
observed in 46/56 individuals who were not resistant to stand-
ard immunosuppressive therapy. The standard regimen could
not induce clinical remission and ANCA titer reduction in 10/
56 patients, necessitating introduction of additional immuno-
suppressive therapy including plasmapheresis in three and
intravenous immunoglobulins (2 g/kg) in seven patients,
respectively. No patient in the ATD-treated group had to be
treated with additional immunosuppressive therapy.
In the ISV group, chronic renal failure was statistically more fre-
quent (p < 0.01) than in ATD-treated ANCA-positive patients
(Table 5). There were no differences in terminal renal failure (p
> 0.05) between the groups. In 2/16 ATD-treated patients, the
drugs (MM 20 mg/day and PTU 250 mg/day, respectively)
were not discontinued in time, and they developed terminal
renal failure and chronic renal failure, respectively. Both
patients had ATD-induced MPA during a relapse of GD. ATD-
Table 4
Differences in clinical and serological characteristics of PR3/MPO-ANCA positive antithyroid DIDs
Antithyroid drug-induced vasculitides (n = 4) Antithyroid drug-induced LLD (n = 12)
Age, years (range) 35 ± 6 (20–40) 30 ± 8 (25–52)
Female 3 (75) 12 (100)
Graves' disease 4 (100) 9 (75)
Hashimoto thyroiditis 0 3 (25)
Florid hyperthyroidism 4 (100) 3 (25)
Relapse of hyperthyroidism 2 (50) 4 (33.3)
Antimicrosomal Ab 3 (75) 10 (83.3)
Antithyroid drug therapy, months 21 ± 6 18 ± 7
Months between first complaints and ANCA 
detection
3 ± 1.5 2 ± 1
Propylthiouracil 2 (50) 10 (83.3)
Methimazole 2 (50) 2 (16.7)
Renal manifestations 2 (50) 1 (8.3)
Lung manifestations 3 (75) 0
Skin manifestations 0 10 (83.3)
PANCA 3 (75) 12 (100)
CANCA 1 (25) 0
MPO-ANCA (U/ml) 65 ± 20 53 ± 15
PR3-ANCA (U/ml) 44 -
ANA 0 8 (66.6)
aCL IgG, IgM 0 9 (75)
Anti-β 2 GP I IgG, IgM 0 4 (33.3)
Cryoglobulinemia 0 3 (25)
Low C4 (<0.1 g/l) 0 3 (25)
High CR-P (>10 mg/l) 4 (100) 4 (33.3)
Leucopenia (<3 × l09/l) 0 2 (16.7)
All values represent either numbers of patients (%), or mean ± standard deviation. Ab, antibodies; aCL, anticardiolipin antibodies; ANA, 
antinuclear antibodies; anti-β 2 GP I, anti-beta 2 glycoprotein I; cANCA, cytoplasmic antineutrophil cytoplasmic antibodies; CR-P, C reactive 
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associated LLD is characterized by a milder course and better
prognosis than ATD-associated MPA (Table 5).
In the ISV group, lethal outcome was more frequent (p  =
0.059) than in the DID group. In the ISV group, 6/56 patients
died during the first episode, while out of the remaining 50, 47
had at least one relapse. In the ATD-treated group there were
no disease relapses.
All the patients with ATD-induced disease are now in remis-
sion without any therapy, whilst the 37/43 patients with ISV
need to receive maintenance therapy (p < 0.001).
After the ATD withdrawal, hyperthyroid patients were treated
with radioactive iodine or subtotal thyroidectomy. In a preg-
nant woman with GD, potassium perchlorate was prescribed
at the lowest dose, keeping the patient mildly hyperthyroid. A
healthy child was born normally 3 months later.
Discussion
Standard clinical and serologic criteria for discrimination of
ANCA-associated ISV from DID are inadequate at the initial
presentation. The histopathology can be inconclusive, since
both entities are characterized by leucocytoclasia and fibrinoid
necrosis of the blood vessels [14]. ANCA-positive DID can be
'pauci-immune' but also with strong vascular immune deposits
[1].
In this 11-year retrospective study, we compared clinical and
serological data from idiopathic and ATD-induced ANCA-pos-
itive patients. A higher number of younger females in the ATD-
treated group was found (Table 1), because hyperthyroidism
is predominantly a disease of this sex and age group [9]. On
the other hand, WG and MPA are predominantly diagnosed in
the older population [1]. ANCA-positive ATD-induced
diseases occur more frequently in GD than in HT [6], which we
also found (Table 1).
All ATDs can induce asymptomatic production of ANCA, but
PTU most often induces ANCA-associated MPA or LLD [15].
In our study, apart from long-term ATD use [16], the repeated
use of ATDs was also a risk factor for developing the disease.
As PTU is more commonly associated with ANCA-positive
DID, MM may be the preferred medication if hyperthyroidism is
combined with other autoimmune diseases [17]. At the molec-
ular level, PTU and MM are based on thionamide, and the
substitution of one with the other should be undertaken with
caution. On the other hand, patients should be promptly
brought to euthyroid state. Since MM is contraindicated in
pregnancy, PTU-induced disease in pregnancy demands cau-
tious use of iodides [18]. This enabled a successful delivery in
one of our patients.
The analysis of the clinical parameters (Table 2) showed that
the first symptoms (arthralgias and myalgias) of ANCA-posi-
tive ISV and ATD-treated patients were similar. Shorter dura-
t i o n  o f  t h e  s y m p t o m s  b e f o r e  d i a g n o s i s  ( T a b l e  1 )  i n  A T D -
Table 5
Disease activity and ANCA titers at presentation, treatment and outcome in study groups.
Patients with idiopathic vasculitides (n = 56) Patients with antithyroid DIDs (n = 16)
WG n = 29 MPA n = 23 CSSy n = 4 WG n = 1 MPA n = 3 LLD n = 12
BVAS 21.37 19.78 20.0 15 13. 0 -
cANCA, n 2 8 00100
cANCA, l/titer, median 128 - - 64 - -
pANCA, n 12 34 - 31 2
pANCA,1/titer, median 64 256 128 - 128 256
Cyclophosphamide, n 29 23 4 1 2 0
Only corticosteroids n 000012
cANCA after 6 months, 1/ titer, median 16* - - 8 - -
pANCA after 6 months, 1/titer, median 8 16 - - 32 128
CRF, n 14 10 1 0 1 0
TRF, n 260010
Lethal outcome, n 1 1 20000
Patients with relapses, n 23 22 2 0 0 0
*Median titer of 23 WG patients, six died at first presentation. BVAS, Birmingham Vasculitis Activity Score; cANCA, cytoplasmic antineutrophil 
cytoplasmic antibodies; CRF, chronic renal failure; CSS, Churg Strauss syndrome; DID, drug-induced autoimmune disease; LLD, lupus-like 
disease; MPA, microscopic polyangiitis; pANCA, perinuclear antineutrophil cytoplasmic antibodies; TRF, terminal renal failure; WG, Wegener's 
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treated patients can be explained by a higher percentage of
early skin manifestations. Although arthralgias, myalgias and
weight loss can be seen in hyperthyroidism, temperature
peaks over 38.5°C, and renal and pulmonal involvement are
unusual [9]. Sera et al. [19] followed 21 MPO-ANCA-positive
patients treated with PTU: 12 had no symptoms but nine
patients complained of myalgia, arthralgia or common cold-like
symptoms after the appearance of MPO-ANCA.
ANCA-associated pulmonary-renal syndrome is the most
severe presentation of necrotizing vasculitis. In ATD-treated
patients, renal lesions may be mild but also fulminant, including
development of ARF [20]. One MM-treated patient developed
drug-induced WG, which is a very rare form of DID [21]. After
discontinuing ATD, our patient was treated orally with cyclo-
phosphamide and prednisone for 3 months, while Pillinger et
al. induced remission of WG only by discontinuing PTU [21].
Cutaneous changes in ANCA-positive ATD-treated patients
can vary enormously from maculopapular exanthema to pyo-
derma gangrenosum, cutaneous ulcerations and vesiculo-bul-
lous lesions typical for bullous SLE [22,23]. Of our patients, 7/
16 had urticaria and urticaria-like vasculitis while two had
extensive cutaneous necrosis (Table 2). Urticaria-like vasculitis
is frequently seen in patients with hypo-complementemic vas-
culitis and SLE. Gangrene and cutaneous necroses are poor
signs of PR3-ANCA-positive ISV [24]. However, cutaneous
necroses in our two ATD-treated ANCA-positive patients were
not associated with a worse prognosis.
An analysis of the serologic profile of the ATD-treated patient
group showed simultaneus presence of various autoantibod-
ies (Table 3). In patients with GD and HT, even before starting
ATD, different ANA were found [25], as well as different organ-
specific autoantibodies.
On the other hand, most patients with GD and HT who were
not treated with ATD do not have ANCA [19]. In the PTU-
treated group, 25% of the patients had MPO-ANCA, while in
the MM group only 3.4% had MPO-ANCA [15]. These find-
ings suggest that the altered immune environment associated
with GD and HT is not sufficient to develop ANCA, but treat-
ment with ATD induces ANCA production.
The titer of pANCA was much higher in the ATD-treated group
than in the ISV group, while concentrations of MPO-ANCA did
not differ (Table 3). We suppose that patients taking ATD have
ANCA specific to elastase and lactoferrin, which was
described in PTU-induced vasculitis and LLD [26]. PTU is also
associated with simultaneous production of MPO-ANCA and
PR3-ANCA [26], which however, we did not see in any of our
patients. It was shown that WG patients during ATD therapy
changed PR3-ANCA to MPO-ANCA with flares of vasculitis
[27].
The pathogenic role of ANCA remains controversial in ISV and
DID. Because not all ANCA-positive patients develop the dis-
ease, some authors are considering, along with ATD, an infec-
tion as an additional trigger in inducing autoimmune diseases
[20]. In our series of ATD-associated ANCA-positive patients,
there were no clinical or laboratory parameters for infection.
However, an unnoticed mild viral infection might induce prim-
ing (TNF-alfa) of neutrophils and translocation of PR3 and
MPO to the cell surface [2,28].
Some authors are considering the possibility of cross-over
epitopes between thyroid peroxidase and MPO [29]. We
showed that only some MPO-ANCA-positive patients have
antimicrosomal antibodies (Table 3). Besides 44% homology
in amino acid sequences, there is no cross-reactivity between
thyroid peroxidase and MPO [30].
On the other hand, it was shown that PTU accumulates in neu-
trophils, binds to MPO and induces production of cytotoxic
products [31,32]. It has been suggested that some drugs
could induce neutrophil apoptosis [33]. Moreover, neutrophil
apoptosis, in the absence of priming, is associated with trans-
location of ANCA antigens to the cell surface [34]. Simultane-
ous presence of various autoantibodies (anti-DNA, AHA, anti-
SSA, aCL and anti-β 2 GP I) suggest that apoptotic blebs of
neutrophils could be a source of immunogens in our patients
with ATD-induced LLD [35,36].
ATD-induced ANCA-positive diseases are divided in two
groups (Table 4). The first group (4/16) consisted of PR3- or
MPO-ANCA-positive drug-induced WG or MPA which resem-
ble ISV. The second group (12/16) consisted of MPO-ANCA-
positive patients with LLD. We speculate that different
clearance of apoptotic materials by macrophages might deter-
mine type of autoimmune response [37]. PTU-induced LLD
was described in a patient with HLA DR9 haplotype whose
twin sister had SLE [38].
Our ATD-associated LLD patients, despite high concentration
of MPO-ANCA, had mild clinical courses. IgM anti-MPO
antibody-secreting lymphocytes are present in the peripheral
repertoire of lupus-prone mice but rarely differentiate into IgG-
producing cells [39]. We can suppose that ATDs induce pro-
duction of the potentially pathogenic MPO-ANCA IgG4 sub-
class [40]. MPO has the characteristics of a SLE-related
antigen [39]. MPO-ANCA in SLE is most often found in the
context of secondary APS [41], for which there were no crite-
ria in our patients. Anti-β 2 GP I antibodies are typical markers
for APS [13] and have not been reported in ATD-induced
ANCA-positive diseases. These data may have an impact on
the approach to the patients since thrombotic events can be
expected in case of an infection or a surgical procedure.
Simultaneous presence of cryoglobulins, aCL and anti-β 2 GP
I antibodies [42] in our two MPO-ANCA-positive patients withAvailable online http://arthritis-research.com/content/7/5/R1072
R1080
LLD synergistically contributed to development of cutaneous
necrosis. However, we can assume that in patients with ISV,
absolute or relative deficiency of α 1 AT (Table 3), which is a
specific PR3 inhibitor, could play a role in necrosis. The clinical
picture of ISV depends on alotypic polymorphism of the Fcγ
receptors, the isotype of PR3-ANCA or MPO-ANCA, and avid-
ity as well as functionality of α 1 AT [2]. Bearing in mind all
these factors, it is clear that the ANCA titer in our patient with
ISV did not correlate with BVAS (p > 0.05). Higher CR-P val-
ues in patients with ISV (Table 3) point to more intensive
necrosis and inflammation than in indviduals with ATD-
induced diseases.
Generally, ISV patients (Table 5) have a more severe course,
demand more intensive immunosuppressive therapy, and have
frequent relapses which we have not observed in ANCA-pos-
itive ATD-treated patients.
Therefore, patients with GD and HT should be carefully fol-
lowed and monitored, not only for their thyroid status but also
for the serious complications of ATD therapy. Patients with
positive ANCA without evidence of vasculitis should also be
carefully followed. The onset of urticaria-like vasculitis, erythro-
cyturia or pulmonary complaints demand immediate discontin-
uation of ATD.
Conclusion
Our results show that ATDs are frequent exogenous trigger
factors of ANCA-associated autoimmune diseases. In compar-
ison with drug-induced disease, ISV patients had a severe
course with more frequent renal, pulmonal and neurologic
manifestations. In contrast to patients with ISV, ATD-induced
ANCA-positive patients had skin manifestations more fre-
quently, especially urticaria-like vasculitis. ATD can induce two
clinically and serologically different types of diseases. Simulta-
neous presence of various autoantibodies characterizes ATD-
induced MPO-ANCA-positive LLD with good prognosis. On
the other hand, ATD-induced MPO or PR3-ANCA-positive life-
threatening MPA or WG resemble ISV and were not associ-
ated with organ-nonspecific autoantibodies. Different serolog-
ical profiles could help in the differential diagnosis and
adequate therapeutic approach to ANCA-positive ATD-
treated patients with symptoms of systemic disease.
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